First-Line Atezolizumab Monotherapy vs Single-Agent Chemotherapy in Patients With NSCLC Ineligible for Treatment With a Platinum-Containing Regimen
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study
Lancet 2023 Jul 06;[EPub Ahead of Print], SM Lee, C Schulz, K Prabhash, D Kowalski, A Szczesna, B Han, A Rittmeyer, T Talbot, D Vicente, R Califano, D Cortinovis, AT Le, D Huang, G Liu, F Cappuzzo, J Reyes Contreras, M Reck, R Palmero, MP Mak, Y Hu, S Morris, E Höglander, M Connors, AM Biggane, HK Vollan, S PetersFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.